Survival is related to the reduction of megakaryopoiesis in chronic myelomonocytic leukemia (CMML)Clinical, haematological and outcome data were studied in 84 patients with acquired idiopathic sideroblastic anaemia (AISA) from a registry of 613 consecutive myelodysplastic syndromes (MDS) recorded by five...
CMML is a rare form of leukemia characterized by high levels of monocytes in the blood. The main symptoms are abdominal pain and feeling full too soon while eating. It is not clear what causes CMML but it can occur after treatments for other cancers. The only cure for CMML is a stem ce...
acute myeloid leukemia; AZA, azacitidine; BM-CR, bone marrow complete response; CMML, chronic myelomonocytic leukemia; CR, complete response; CRi, morphologic CR with incomplete blood count; MDS, myelodysplastic syndromes; NA, not analyzed; NE, not estimable; OS, overall survival; PAN, panobinostat...
AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.
Given the advanced age, only 3 (9%) went on to transplant. Cox-regression analysis only associated post-treatment RBC TI with survival with no observed effect on OS for other baseline or response-related factors; the sensitivity of these analyses is limited by patient number. DEC/CED has ...
, European Blood and Marrow Transplantation Group (EBMT), Chronic Leukemia Working Party (CLWP)-MDS subcommittee Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival Br J Haematol...
65 Survival and outcome in 30 patienta with chronic myelomonocytic leukemia (CMML)doi:10.1016/S0145-2126(97)81277-5M. Shtarlid and L. Shvidel and A. Klepfish and E. Sigler and A. BerrebiLeukemia Research
SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survivaldoi:10.1182/bloodadvances.2020003345Kitsada WudhikarnSanam LoghaviAbhishek A MangaonkarAref Al-KaliMrinal M PatnaikBlood Advances
86 ALLOGENEIC TRANSPLANTATION FOR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) IS ASSOCIATED WITH HIGH DISEASE-FREE SURVIVAL EVEN IN THE SETTING OF HIGH-RISK DISEASEdoi:10.1016/S0145-2126(15)30087-4M.SanchezK.AbbiR.TamariA.JakubowskiE.Papadopoulos
By the WHO classification, the majority of patients had CMML-1 (84% vs. 16%) and most patients were subcategorized as MPN-CMML (59%) versus MDS-CMML (39%) by the FAB CMML criteria. The median overall survival of the entire cohort was 30 months and the rate of AML transformation was...